Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

The growing range of complications of diabetes mellitus

Trends in Endocrinology and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Association between cardiovascular health and metabolic dysfunction-associated steatotic liver disease: a nationwide cross-sectional study

Journal of Health Population and Nutrition, Journal Year: 2025, Volume and Issue: 44(1)

Published: Jan. 13, 2025

Evidence concerning the effect of cardiovascular health (CVH) on risk metabolic dysfunctional-associated steatotic liver disease (MASLD) is scarce. This study aimed to investigate association between CVH and MASLD. 5680 adults aged ≥ 20 years from National Health Nutrition Examination Survey 2017-March 2020 were included. Life's essential 8 (LE8) was applied assess CVH. Weighted binary logistic regression employed calculate odds ratio (OR) 95% confidence interval (CI) with Restricted cubic spline (RCS) conducted explore dose-response LE8 its subscales scores Among participants, 724, 3901, 1055 had low, moderate, high levels, respectively, a MASLD diagnosis prevalence 36.83%. In fully adjusted model, ORs for 0.50 (95% CI, 0.37–0.69) participants moderate 0.21 0.13–0.34) those CVH, when compared low (P < 0.001 trend). OR 0.68 0.61–0.77) each 10-point increase in score. RCS model demonstrated non-linear relationship score factors MASLD, while linear found behaviors Subgroup analysis showed consistent negative correlation sensitivity validated reliability these findings. Higher associated lower Encouraging adherence optimal levels may help mitigate burden

Language: Английский

---

Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action

Diabetes Spectrum, Journal Year: 2024, Volume and Issue: 37(1), P. 5 - 7

Published: Feb. 1, 2024

Language: Английский

---

Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know

Diabetes Spectrum, Journal Year: 2024, Volume and Issue: 37(1), P. 29 - 38

Published: Feb. 1, 2024

Standards of care summarized in clinical practice guidelines for nonalcoholic fatty liver disease (NAFLD) offer clinicians a streamlined diagnostic and management approach based on the best available evidence. These recommendations have changed great deal recent years; today, there is clear focus screening early identification risk stratification patients at high steatohepatitis clinically significant fibrosis to promote timely referrals specialty when needed. This article reviews provides rationale current NAFLD screening, diagnosis, treatment, monitoring addresses barriers providing evidence-based how overcome them. The paradigm calls primary specialists work together, within multidisciplinary team familiar with obesity diabetes care, provide comprehensive these complex patients.

Language: Английский

---

“Evaluation of Curcuma zedoaria Rosc. in the management of non-alcoholic fatty liver Disease: A Randomized, single blind, controlled trial”

Arab Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Reactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH

Nutrients, Journal Year: 2025, Volume and Issue: 17(4), P. 610 - 610

Published: Feb. 7, 2025

Background: Products of lipid peroxidation include a number reactive aldehydes including dicarbonyl electrophiles (DEs) and contribute to disease processes. DEs play significant role in the development progression metabolic-associated steatotic liver (MASLD) by contributing oxidative stress, inflammation, protein dysfunction, mitochondrial impairment. Reducing DE stress may be potential strategy for managing MASLD. We hypothesized that scavenger 2-hydroxybenzylamine (2-HOBA) would reduce injury reducing adduct formation mouse models Methods: Protein adducts were measured human livers immunohistochemistry immunoblot. The effects 2-HOBA assessed two different Results: Isolevuglandin (IsoLG) increased MASH-staged relative histologically normal controls. Diet-Induced Animal Model Nonalcoholic Fatty Liver Disease (DIAMOND) mice treated with exhibited significantly lower fibrosis scores (* p = 0.012) reduced transaminases (AST, 0.03) ALT, over 40%. In STAM (Stelic Model) mice, improved NAFLD activity (p 0.03, NAS), hyperglycemia, inflammatory cytokines serum F2-isoprostanes (IsoPs) 30%, 0.05. These improvements absent mRNA changes hepatic antioxidant enzymes (Cat, Gpx1, or Sod2) ROS-generating proteins (p22PHOX, p47PHOX, NOX4 COX1). Conclusions: scavenging promising therapeutic While findings are currently limited male nutraceutical reduces could improve management MASH offering non-invasive treatment option potentially slow reverse scarring, delay cirrhosis, patient outcomes, while also providing patients who not suitable other interventions like transplantation.

Language: Английский

---

Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1978 - 1978

Published: March 14, 2025

The last two decades have proffered many remarkable choices in managing type 1 and 2 diabetes mellitus. Leading the list are glucagon-like peptide-1 receptor agonists (GLP1RAs), first of which, exenatide, was approved by FDA 2005. Two other major classes drugs also entered market: dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins 2006, sodium–glucose cotransporter-2 (SGLT-2) with approval occurring 2013. These revolutionized treatment diabetes. Additionally, on horizon, once-weekly basal insulin analog icodec combination semaglutide expected to be available future. Beyond glycemic control, GLP1RAs exhibited benefits conditions associated diabetes, including hypertension, dyslipidemia, non-alcoholic steatohepatitis, well neurodegenerative diseases such Alzheimer’s disease. emerging research suggests potential roles certain types cancer, infertility, associative learning. Major cardiovascular events seem lower patients GLP1RAs. While some evidence is robust, findings remain tenuous. It important that clinicians familiar current order provide optimal evidence-based care patients. In not-too-distant future, there may a case prescribe these for outside

Language: Английский

---

Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease

Russian Journal of Gastroenterology Hepatology Coloproctology, Journal Year: 2025, Volume and Issue: 35(1), P. 94 - 152

Published: March 9, 2025

Aim . The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care patients with non-alcoholic fatty liver disease, taking into account latest data principles evidence-based medicine. Key points Clinical contain about current views on etiology, risk factors pathogenesis nonalcoholic peculiarities its course. Also given recommendations methods laboratory instrumental diagnostics, invasive non-invasive tools disease phenotypes assessment, approaches treatment, considering presence comorbidities, features dispensary monitoring prophylaxis. is illustrated algorithms differential diagnosis physician's actions. In addition, there patient criteria assessing care. Conclusion Awareness specialists in issues diagnosis, treatment follow-up contributes timely initiation which long term significantly affect their prognosis life.

Language: Английский

---

Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD

Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(9), P. 101714 - 101714

Published: Sept. 1, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence is increasing annually and affects over a third of US adults. MASLD can progress to metabolic steatohepatitis (MASH), characterized by severe hepatocyte injury, inflammation, eventual advanced fibrosis or cirrhosis. MASH predicted become the primary cause transplant 2030. Although etiology MASLD/MASH incompletely understood, dysregulated fatty acid oxidation implicated in pathogenesis. Here, we develop method for estimating hepatic β-oxidation from metabolism [D

Language: Английский

---